-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

617A.O2.6 617. Acute Myeloid Leukemias: Commercially Available Therapies: How Do We Start? Upfront Regimens with Commercially Available Therapies

Symposia: Acute Myeloid Leukemias: Commercially Available Therapies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Combination therapy, Adult, Research, Clinical trials, Elderly, Clinical Research, Chemotherapy, Pediatric, Diseases, Therapy sequence, Treatment Considerations, Real-world evidence, Non-Biological therapies, Adverse Events, Myeloid Malignancies, Study Population, Human, Measurable Residual Disease
Saturday, December 7, 2024: 9:30 AM-11:00 AM
Hall B (San Diego Convention Center)
Moderators:
Shai O. Shimony, MD, and Catherine E. Lai, MD, Abramson Cancer Center, University of Pennsylvania
Disclosures:
Lai: Servier: Other: Advisory board; Daiichi: Other: Advisory board; BMS: Other: Advisory board, Research Funding; AbbVie: Consultancy, Other: Advisory board; Astellas: Consultancy; Rigel: Other: Advisory Board; Genentech: Other: Advisory Board; Jazz: Research Funding.
We picked 6 abstracts that represented a large number of patients with potentially practice changing implications with modifications to existing regimens that are currently used
9:30 AM

Priyanka Mehta, MD, FRCPath, MRCP1*, Roderick Murphy2*, Saemi Park3*, Nalina Dronamraju3*, Tony Wagner4*, Yana Lutska3*, Stefan Faderl4, Ian Thomas5*, Joanna Canham5* and Alex Legg6*

1University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
2Jazz Pharmaceuticals, Oxford, United Kingdom
3Jazz Pharmaceuticals, Philadelphia, PA
4Jazz Pharmaceuticals, Palo Alto, CA
5Centre for Trials Research, Cardiff University, Cardiff, United Kingdom
6Jazz Pharmaceuticals, Oxford, CA, United Kingdom

9:45 AM

Alex Bataller, MD, PhD1*, Hagop M. Kantarjian, MD2, Alexandre Bazinet, MD1*, Jayastu Senapati, MD, DM, MBBS1, Gautam Borthakur, MD3, Nicholas J. Short, MD1, Elias Jabbour, MD4, Koichi Takahashi, MD, PhD5, Naval Daver, MD6, Ghayas C. Issa, MD1, Courtney D. DiNardo, MD, MSc7, Naveen Pemmaraju, MD1, Nitin Jain, MD1, Guillermo Montalban-Bravo, MD1, Guillermo Garcia-Manero, MD1, Farhad Ravandi, MBBS8 and Tapan M. Kadia, MD1

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2University of Texas MD Anderson Cancer Center, Houston, TX
3Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4The University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
6MD Anderson Cancer Center, Houston, TX
7Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
8Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX

10:00 AM

Ioannis Mantzaris, MD1,2, Matan Uriel, MD1*, Mendel Goldfinger2*, Aditi Shastri, MD3,4, Nishi Shah, MBBS, MPH1, Kira Gritsman, MD, PhD1,5, Noah Kornblum, MD1, Lauren Shapiro, MD1, R. Alejandro Sica, MD1, Annemarie Munoz, RN2*, Nicole Chambers, NP1*, Aradhika Dhawan1*, Karen Fehn, RN, BSN2*, Balda Tirone, MHA1*, Lamisha Shah5*, Shaunmonique Clark1*, Mimi Kim, Sc.D6*, Chenxin Zhang6*, Dennis L Cooper, MD2, Amit Verma, MD4,7, Marina Konopleva8,9 and Eric J. Feldman, MD1*

1Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
2Montefiore Einstein Comprehensive Cancer Center, Blood Cancer Institute, Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
3Montefiore Medical Center, Bronx, NY
4Department of Developmental & Molecular Biology, Albert Einstein College of Medicine, Bronx
5Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY
6Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY
7Montefiore Einstein Comprehensive Cancer Center, Blood Cancer Institute, Department of Oncology, Montefiore Health System, Inc., Bronx, NY
8Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx
9Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, NY

10:15 AM

Jules Higué1*, Corentin Orvain2*, Pierre-Yves Dumas, MD, PhD3*, Pierre Peterlin4*, Marie Anne Hospital, MD, PhD5*, Sabrina Barriere6*, Areti Chantzi7*, Audrey Couturier, MD8*, Martin Carre, MD9*, Emmanuelle Tavernier, MD10*, Eric Delabesse, MD, PhD11*, Audrey Bidet, MD12*, Anne Bouvier13*, Marie Joelle Mozziconacci14*, Lauren Veronese, MD15*, Cedric Pastoret, MD PhD16*, Sylvie Tondeur17*, Pascale Flandrin-Gresta18*, Sébastien Lachot7*, Sarah Bertoli, MD19*, Arnaud Pigneux, MD, PhD20* and Christian Récher, MD, PhD21

1Service d'Hematologie, CHU de Toulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
2Maladies du Sang, CHU d’Angers, Angers, France
3Hôpital Haut-Lévèque, Hematology Department, CHU Bordeaux, Pessac, France
4Hematology Department, Hôtel-Dieu University Hospital, NANTES CEDEX 1, France
5Department of Hematology, Institut Paoli-Calmettes, Marseille, France
6Hematology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France
7Hematology Department, CHU de Tours, Tours, France
8CHU de Rennes, Rennes, France
9Clinical Hematology Department, CHU Grenoble Alpes - Université Grenoble Alpes, Grenoble, France
10Département d'hématologie Clinique et de Thérapie Cellulaire, CHU Saint-Etienne, Saint-Etienne, France
11IUCT-Oncopole, Hematology Laboratory, CHU de Toulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
12Laboratoire d’Hématologie Biologique, CHU Bordeaux, Bordeaux, France
13Angers University Hospital, ANGERS, AL, FRA
14Department of Biopathology, Institut Paoli-Calmettes, Marseille, France
15Centre Hospitalier Universitaire Clermont-Ferrand, Clermont Ferrrand, FRA
16Rennes University Hospital, RENNES, FRA
17Grenoble Alpes University Hospital, Grenoble, FRA
18University Hospital of Saint-Etienne, Saint-Etienne, Florida, FRA
19IUCT-Oncopole, Hematology Department, CHU de Toulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
20Centre Hospitalier Universitaire de Bordeaux, Hôpital Haut Lévêque - Centre François Magendie, Pessac, France
21Hematology Department, CHU deToulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France

10:30 AM

Steven Knapper, DM1, Laura W Dillon, PhD2*, Malavika Babu3*, Abin Thomas3*, Ian Thomas3*, Christopher S. Hourigan, DM, DPhil4, Georgia Andrew, BSc2*, Richard Dillon, MA5, Amanda Gilkes, PhD1*, Nuria M Almuina3*, Sophie King3*, Thomas Coats, MBBS, PhD, FRCPath6*, Nicholas McCarthy7*, Jennifer Byrne, FRCP FRCPath PhD8*, Simone Green, MBBS, FRCPath9*, Ulrik Malthe Overgaard10*, Leanne Berkahn, MD11, Louisa Stone12*, Rasha W Al-Ali13*, Reem Bahr14*, Rob Sellar, FRCPath, MBBChir15*, Mike Dennis, MD, MRCP, FRCPath16, Priyanka Mehta, MD, FRCPath, MRCP17*, Robert K Hills18*, Sylvie D Freeman19 and Nigel H. Russell, MD20

1Department of Haematology, Division of Cancer & Genetics School of Medicine, Cardiff University, Cardiff, United Kingdom
2Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD
3Centre for Trials Research, Cardiff University, Cardiff, United Kingdom
4Myeloid Malignancies Program, National Institutes of Health, Bethesda, MD
5Department of Medical and Molecular Genetics, King's College London, London, United Kingdom
6Royal Devon & Exeter NHS Foundation Trust Wonford Site, Exeter, ENG, United Kingdom
7University of Birmingham, UK, Birmingham, GBR
8Nottingham University Hospitals NHS Trust, Nottingham, GBR
9Castle Hill Hospital, Hull, United Kingdom
10Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
11Haematology Department, Auckland City Hospital, and Australasian Leukaemia and Lymphoma Group, Auckland, New Zealand
12Auckland City Hospital, Auckland, New Zealand
13Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, DC
14Virginia Tech, Charlottesville, VA
15University College London, London, GBR
16The Christie NHS Foundation Trust, Manchester, United Kingdom
17University Hospitals Bristol NHS Foundation Trust, Bristol, GBR
18University of Oxford, Oxford, GBR
19University of Birmingham, Birmingham, United Kingdom
20Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

10:45 AM

Shai O. Shimony, MD1, Heardley Murdock, MD1, Julia Keating, MS2*, Christopher R. Reilly, MD1, Harrison K. Tsai, MD, PhD3,4*, Christopher J. Gibson, MD5, Stefan Faderl6, Tony Wagner6*, Nalina Dronamraju6*, Tara L. Lin, MD7, Ellen K. Ritchie, MD8, Thomas Prebet, MD, PhD9*, Jorge E. Cortes, MD10, Geoffrey L. Uy, MD11, Jeffrey E Lancet, MD12, Donna S. Neuberg, ScD2, Richard M. Stone, MD1 and R. Coleman Lindsley, MD1

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
3Department of Pathology, Brigham and Women's Hospital, Boston, MA
4Department of Pathology, Boston Children’s Hospital, Boston, MA
5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
6Jazz Pharmaceuticals, Palo Alto, CA
7Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS
8Weill Cornell Medicine and The New York Presbyterian Hospital in New York City, New York, NY
9Bristol Myers Squibb, Princeton, NJ
10Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA
11Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO
12Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

*signifies non-member of ASH